Histone deacetylase inhibitors turn on genes that are turned off by Myc proteins, Australian research shows.

'Guardian of the genome' predicts treatment outcomes for childhood cancer.

Study finds Abbott Laboratories' ABT-737 increases therapy effectiveness.

A new cancer research facility will be built at the University of NSW.

Australian scientists identify cells responsible for relapse after treatment in common childhood cancer.

Resistance to glucocorticoid therapy remains an important factor in the battle to achieve high cure rates in childhood leukaemia. Researcher Richard Lock has helped develop a xenograph model to identify drug resistance mechanisms.

Sydney's Children's Cancer Institute Australia (CCIA) has joined leading paediatric cancer institutes in the US including St Jude Children's Research Hospital, Children's Hospital of Los Angeles, Children's Hospital of Philadelphia, Duke University Medical Centre, and Memorial Sloan- Kettering Cancer Centre to test new cancer drugs for the treatment of childhood cancers.